SAGE

Sage Therapeutics Inc

SAGE.US sagerx.com + Research + Basket
CIK 0001597553
Employees 353
Phone 617 299 8380
Fiscal year end December
IPO Jul 18, 2014
Address 55 Cambridge Parkway, Cambridge, MA, United States, 02142
Price N/A
USD · NASDAQ
52-week range
0.00
0.00
Market Cap
544.94M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
5.89
Div. Yield
N/A
% Institutions
83.60%
% Insiders
10.36%

1 Year

-20.7%

3 Year

-74.8%

10 Year

-87.2%
Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults. Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders. In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. As of July 31, 2025, Sage Therapeutics, Inc. operates as a subsidiary of Saphire, Inc.

Actions

Add an action for SAGE.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Barry E. Greene President, CEO & Director 1963
Mr. Christopher Benecchi COO & Treasurer 1972
Mr. Gregory Shiferman Senior VP, General Counsel & Secretary NA
Mr. Michael Quirk Ph.D. Chief Scientific Officer & Interim Head of R&D NA
Ms. Ashley Kaplowitz Director of Investor Relations NA
Ms. Pamela Herbster Senior VP and Chief People & Experience Officer NA
Dr. Helen Colquhoun Senior Vice President of Drug Safety & Pharmacovigilance NA
Dr. Aaron Koenig M.D. Medical Director of Early Clinical Development NA
Helen Rubinstein Investor Relations Officer NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Aug 09, 2023 Elizabeth Barrett N/A Purchase 2.00K $18.64 $37.28K SEC
May 09, 2023 Elizabeth Barrett N/A Purchase 1.00K $50.50 $50.50K SEC
Feb 10, 2023 Jeffrey M Jonas N/A Sale 11.64K $44.61 $519.39K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Madison Avenue Partners, LP 6.08M Jun 30, 2025 9.68% $3.70 35.72%
BlackRock Inc 4.66M Mar 31, 2025 7.42% $0.00 -3.91%
Vanguard Group Inc 3.27M Jun 30, 2025 5.20% $0.00 -35.68%
D. E. Shaw & Co LP 1.92M Jun 30, 2025 3.05% $0.01 -8.15%
Morgan Stanley - Brokerage Accounts 1.40M Mar 31, 2025 2.23% $0.00 -69.55%
BOOTHBAY FUND MANAGEMENT, LLC 1.38M Mar 31, 2025 2.21% $0.29 -0.29%
Geode Capital Management, LLC 1.30M Mar 31, 2025 2.08% $0.00 3.70%
Eckert Corp 1.27M Jun 30, 2025 2.03% $0.62 0.00%
State Street Corp 1.19M Mar 31, 2025 1.89% $0.00 -6.61%
683 Capital Management LLC 1.15M Jun 30, 2025 1.83% $0.69 15.00%
Marshall Wace Asset Management Ltd 1.15M Jun 30, 2025 1.83% $0.01 -34.86%
The Toronto-Dominion Bank 1.08M Jun 30, 2025 1.72% $0.02 0.00%
Qube Research & Technologies 1.08M Jun 30, 2025 1.72% $0.01 0.00%
Citadel Advisors Llc 1.05M Mar 31, 2025 1.67% $0.00 1,144.28%
Harvest Management LLC 889.20K Jun 30, 2025 1.42% $3.45 22.45%
Dimensional Fund Advisors, Inc. 874.17K Jun 30, 2025 1.39% $0.00 81.45%
AQR Capital Management LLC 861.37K Jun 30, 2025 1.37% $0.01 -24.86%
Renaissance Technologies Corp 769.70K Mar 31, 2025 1.23% $0.01 70.74%
ADAR1 Capital Management LLC 742.50K Mar 31, 2025 1.18% $1.10 3,767.16%
Newtyn Management LLC 700.00K Jun 30, 2025 1.12% $0.97 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 BB Biotech AG Ord 4.46M 7.11% ▲ 0.00% Dec 31, 2024
2 Fidelity Small Cap Index 568.57K 0.91% ▲ 3.42% Jun 30, 2025
3 Nuveen Quant Small Cap Equity R6 427.73K 0.68% ▼ 1.96% Jun 30, 2025
4 Fidelity Extended Market Index 294.36K 0.47% ▼ 0.26% Jun 30, 2025
5 Schwab US Small-Cap ETF™ 256.13K 0.41% ▲ 0.00% Jul 31, 2025
6 Federated Hermes MDT SCC Institutional 209.67K 0.33% ▼ 74.48% Jun 30, 2025
7 Federated Hermes MDT Small Cap Core IS 209.67K 0.33% ▼ 74.48% Jun 30, 2025
8 Vanguard Growth & Income Inv 206.42K 0.33% ▲ 7.40% Jun 30, 2025
9 Prisma Global 190.00K 0.30% ▼ 19.83% Mar 31, 2025
10 Lazard US Sm Cap Eq WW Dist EUR 173.50K 0.28% ▲ 0.00% May 31, 2025

Financial Highlights

▼
Market Cap: $544.94M
EBITDA: $-302.08M
PEG Ratio: $0.74
Book Value: $5.89
Earnings/Share: $-4.89
Profit Margin: 0.00%
Operating Margin: -171.19%
ROA (TTM): -33.78%
ROE (TTM): -60.43%
Revenue (TTM): $70.41M
Revenue/Share (TTM): $1.14
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 265.80%

Valuation Metrics

Enterprise Value: $190.79M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 62.78M
Shares Float: 51.31M
% Insiders: 10.36%
% Institutions: 83.60%
Shares Short: 2.22M
Shares Short (Prior Month): 2.81M
Short Ratio: 0.65
Short % Float: 3.94%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$41.24M
Cost of Goods Sold
adjust
$-9.44M
Gross Profit
subtotal
$31.80M
SG&A
adjust
$-216.42M
R&D
adjust
$-225.90M
Other Operating Expense
adjust
$-21.85M
Operating Income
subtotal
$-432.37M
Other / Non-Operating Items
adjust
$31.70M
Net Income
subtotal
$-400.67M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about SAGE.US!